Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00807755 · ClinicalTrials.gov registry record · Phase 1
Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors
A Phase 1 study, sponsored by University of California, Davis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT00807755 is a Phase 1 study that was terminated before completion, run by University of California, Davis. The registered enrollment target is 5 participants.
The verdict
NCT00807755, a Phase 1 study, was terminated before completion, sponsored by University of California, Davis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as carboplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) together with everolimus may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of everolimus, carboplatin, and etoposide in treating patients with small cell lung cancer or other advanced solid tumors.
Interventions
- DRUG Carboplatin
- DRUG Etoposide
- DRUG RAD001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00807755
The ClinicalTrials.gov registry entry for NCT00807755 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT00807755 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00807755 about?
NCT00807755 is a clinical study titled "Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors". RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as carboplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cell...
What is the current status of trial NCT00807755?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2009-03. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00807755?
The interventions under investigation include: Carboplatin (DRUG), Etoposide (DRUG), RAD001 (DRUG).
Who is sponsoring clinical trial NCT00807755?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.